Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591160 · ClinicalTrials.gov registry record · NA
Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism
A NA study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02591160 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 2 participants.
The verdict
NCT02591160, a NA study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the ambulatory setting. PHPT may be cured with surgery and indications for intervention have been defined and include urinary calcium/creatinine clearance. Hydrochlorothiazide (HCTZ), the most commonly prescribed medication for hypertension, reduces urinary calcium excretion and confounds urinary testing. As a result, it is universally recommended that thiazide diuretics be stopped in advance of urinary testing. To date, no studies are available to provide evidence-based guidance as to how long HCTZ must be held for urinary calcium excretion to return to steady state in PHPT. The objective of this study is to serially calculate urinary calcium/creatinine clearance ration in patients with suspected PHPT while holding HCTZ to determine the minimum duration of medication cessation necessary for urinary calcium clearance to reach steady state.
Interventions
- PROCEDURE HCTZ cessation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02591160
The ClinicalTrials.gov registry entry for NCT02591160 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HCTZ cessation is the first listed.
NCT02591160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02591160 about?
NCT02591160 is a clinical study titled "Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism". Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the ambulatory setting. PHPT may be cured with surgery and indications for intervention have been defined and include urinary calcium/creatinine clearance. Hydrochlorothiazide (HCTZ), the most commonly prescribed medicat...
What is the current status of trial NCT02591160?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-05. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT02591160?
The interventions under investigation include: HCTZ cessation (PROCEDURE).
Who is sponsoring clinical trial NCT02591160?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.